Nearly three years after Theravance Inc. and Astellas Pharma US Inc. filed their application for telavancin, a once-daily injectable antibiotic to treat adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), the FDA finally granted approval of the long-embattled drug. (BioWorld World) Read More
